{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:43:43Z","timestamp":1794858223364,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dalian Science and Technology Talent Innovation Project","award":["2024RQ059"],"award-info":[{"award-number":["2024RQ059"]}]},{"name":"The \u201c1 + X\u201d program for large cohort study- -Clinical Research Incubation Project, the Second Hospital of Dalian Medical University","award":["2022DXDL01"],"award-info":[{"award-number":["2022DXDL01"]}],"id":[{"id":"https:\/\/ror.org\/04c8eg608","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The Applied Basic Research Program project of Liaoning Province","award":["2023JH2\/101300074"],"award-info":[{"award-number":["2023JH2\/101300074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study sought to examine the associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease (MASLD) as well as its progression to liver fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study comprised 25,366 subjects aged 18\u00a0years and older, free of MASLD at baseline, from the Dalian Health Management Cohort (DHMC). Cardiometabolic indices include cardiometabolic index (CMI), atherogenic index of plasma (AIP), triglyceride glucose (TyG), triglyceride glucose-body mass index (TyG-BMI), triglyceride glucose-waist circumference (TyG-WC) and triglyceride glucose-waist height ratio (TyG-WHtR). All participants were categorized into quartile groups based on cardiometabolic indices. Cox proportional hazards regression models and restricted cubic splines were employed to examine the relationship between cardiometabolic indices and the incidence of MASLD as well as its progression to liver fibrosis, and analyses were performed between different subgroups. Mediation analysis was employed to explore how obesity and inflammation serve as mediators in the connection between cardiometabolic indices and MASLD. To evaluate the predictive ability of cardiometabolic indices for the onset of MASLD, the time-dependent receiver operating characteristic (ROC) curve was utilized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 5378 (21.2%) individuals developed MASLD during the follow-up period of 82,445 person-years. Multivariates Cox regression analyses showed that participants in the highest quartile of cardiometabolic indices had greater risk of MASLD than those in the lowest quartile (CMI: HR\u2009=\u20096.11, 95% CI 5.45\u20136.86; AIP: HR\u2009=\u20094.58, 95% CI 4.11\u20135.10; TyG: HR\u2009=\u20093.55, 95% CI 3.21\u20133.92; TyG-BMI: HR\u2009=\u200913.55, 95% CI 11.80\u201315.57; TyG-WC: HR\u2009=\u200912.52, 95% CI 10.93\u201314.34; TyG-WHtR: HR\u2009=\u200911.37, 95% CI 9.96\u201312.98). TyG-BMI (HR\u2009=\u20091.36, 95% CI 1.18\u20131.57), but not other cardiometabolic indices, was associated with liver fibrosis. Mediation analysis indicated that BMI mediated 40.4%, 33.2%, 36.5%,\u2009\u2212\u200910.4%, 37.4%, 48.5% of the associations between CMI, AIP, TyG, TyG-BMI, TyG-WC, TyG-WHtR and MASLD. Time-dependent ROC curves demonstrated that TyG-BMI had a superior predictive ability for MASLD onset compared to other indicators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The risk of developing MASLD increases as the level of cardiometabolic indices increases. Obesity may serve as a mediating factor in the aforementioned association. TyG-BMI showed the strongest association with the onset of MASLD and its progression to liver fibrosis, proved to be outperformed other cardiometabolic indicators, and could be the best clinical non-invasive biomarker for early screening of MASLD and liver fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-025-02716-6","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T05:53:02Z","timestamp":1743745982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study"],"prefix":"10.1186","volume":"24","author":[{"given":"Ziping","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinlei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manling","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"3","key":"2716_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver","year":"2024","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@ easloffice.eu, European Association for the Study of Diabetes, European Association for the Study of Obesity, et al. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"6","key":"2716_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"key":"2716_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154170","volume":"111S","author":"A Mantovani","year":"2020","unstructured":"Mantovani A, Scorletti E, Mosca A, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111S: 154170.","journal-title":"Metabolism"},{"key":"2716_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.774079","volume":"8","author":"NLA Segura-Azuara","year":"2021","unstructured":"Segura-Azuara NLA, Varela-Chinchilla CD, Trinidad-Calderon PA. MAFLD\/NAFLD Biopsy-free scoring systems for hepatic steatosis, nash, and fibrosis diagnosis. Front Med (Lausanne). 2021;8: 774079.","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"2716_CR5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35(8):697\u2013707.","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"2716_CR6","first-page":"533","volume":"73","author":"HH Lee","year":"2024","unstructured":"Lee HH, Lee HA, Kim EJ, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. Gut. 2024;73(3):533\u201340.","journal-title":"Gut"},{"issue":"5","key":"2716_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032604","volume":"13","author":"J Gao","year":"2024","unstructured":"Gao J, Li Y, Zhang Y, et al. Severity and remission of metabolic dysfunction-associated fatty\/steatotic liver disease with chronic kidney disease occurrence. J Am Heart Assoc. 2024;13(5): e032604.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2716_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","volume":"22","author":"KE Chan","year":"2024","unstructured":"Chan KE, Ong EYH, Chung CH, et al. Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies. Clin Gastroenterol Hepatol. 2024;22(3):488-498e414.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2716_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/joim.13531","volume":"292","author":"R Paternostro","year":"2022","unstructured":"Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med. 2022;292(2):190\u2013204.","journal-title":"J Intern Med"},{"issue":"Suppl 1","key":"2716_CR10","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.jhep.2021.01.018","volume":"75","author":"R Jalan","year":"2021","unstructured":"Jalan R, D\u2019Amico G, Trebicka J, et al. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. J Hepatol. 2021;75(Suppl 1):S14\u201326.","journal-title":"J Hepatol"},{"issue":"5","key":"2716_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","volume":"36","author":"T Bo","year":"2024","unstructured":"Bo T, Gao L, Yao Z, et al. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease. Cell Metab. 2024;36(5):947\u201368.","journal-title":"Cell Metab"},{"issue":"7","key":"2716_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","volume":"22","author":"T Huby","year":"2022","unstructured":"Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22(7):429\u201343.","journal-title":"Nat Rev Immunol"},{"key":"2716_CR13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cca.2014.08.042","volume":"438","author":"I Wakabayashi","year":"2015","unstructured":"Wakabayashi I, Daimon T. The, \u201ccardiometabolic index\u201d as a new marker determined by adiposity and blood lipids for discrimination of diabetes mellitus. Clin Chim Acta. 2015;438:274\u20138.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"2716_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1373\/clinchem.2004.033175","volume":"50","author":"M Dobiasova","year":"2004","unstructured":"Dobiasova M. Atherogenic index of plasma [log(triglycerides\/HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 2004;50(7):1113\u20135.","journal-title":"Clin Chem"},{"issue":"4","key":"2716_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","volume":"6","author":"LE Simental-Mendia","year":"2008","unstructured":"Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299\u2013304.","journal-title":"Metab Syndr Relat Disord"},{"issue":"3","key":"2716_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149731","volume":"11","author":"LK Er","year":"2016","unstructured":"Er LK, Wu S, Chou HH, et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals. PLoS ONE. 2016;11(3): e0149731.","journal-title":"PLoS ONE"},{"issue":"1","key":"2716_CR17","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12967-016-1020-8","volume":"14","author":"S Zheng","year":"2016","unstructured":"Zheng S, Shi S, Ren X, et al. Triglyceride glucose-waist circumference, a novel and effective predictor of diabetes in first-degree relatives of type 2 diabetes patients: cross-sectional and prospective cohort study. J Transl Med. 2016;14(1):260.","journal-title":"J Transl Med"},{"issue":"1","key":"2716_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12933-023-01839-y","volume":"22","author":"Q Huang","year":"2023","unstructured":"Huang Q, Liu Z, Wei M, et al. The atherogenic index of plasma and carotid atherosclerosis in a community population: a population-based cohort study in China. Cardiovasc Diabetol. 2023;22(1):125.","journal-title":"Cardiovasc Diabetol"},{"key":"2716_CR19","doi-asserted-by":"publisher","first-page":"4914791","DOI":"10.1155\/2022\/4914791","volume":"2022","author":"X Cai","year":"2022","unstructured":"Cai X, Hu J, Wen W, et al. Associations of the cardiometabolic index with the risk of cardiovascular disease in patients with hypertension and obstructive sleep apnea: results of a longitudinal cohort study. Oxid Med Cell Longev. 2022;2022:4914791.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"2716_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12933-024-02278-z","volume":"23","author":"C Cui","year":"2024","unstructured":"Cui C, Qi Y, Song J, et al. Comparison of triglyceride glucose index and modified triglyceride glucose indices in prediction of cardiovascular diseases in middle aged and older Chinese adults. Cardiovasc Diabetol. 2024;23(1):185.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2716_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12933-023-02055-4","volume":"22","author":"C Cui","year":"2023","unstructured":"Cui C, Liu L, Zhang T, et al. Triglyceride-glucose index, renal function and cardiovascular disease: a national cohort study. Cardiovasc Diabetol. 2023;22(1):325.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2716_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12933-024-02336-6","volume":"23","author":"Q Ren","year":"2024","unstructured":"Ren Q, Huang Y, Liu Q, et al. Association between triglyceride glucose-waist height ratio index and cardiovascular disease in middle-aged and older Chinese individuals: a nationwide cohort study. Cardiovasc Diabetol. 2024;23(1):247.","journal-title":"Cardiovasc Diabetol"},{"key":"2716_CR23","doi-asserted-by":"publisher","first-page":"1388017","DOI":"10.3389\/fnut.2024.1388017","volume":"11","author":"Q Wang","year":"2024","unstructured":"Wang Q, Miao X, Hu M, et al. Nonlinear relationship between serum 25-hydroxyvitamin D and lipid profile in Chinese adults. Front Nutr. 2024;11:1388017.","journal-title":"Front Nutr"},{"issue":"1","key":"2716_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12933-023-02001-4","volume":"22","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Yang J, Tang H, et al. High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2023;22(1):263.","journal-title":"Cardiovasc Diabetol"},{"issue":"23","key":"2716_CR25","doi-asserted-by":"publisher","first-page":"7392","DOI":"10.3748\/wjg.v20.i23.7392","volume":"20","author":"SS Lee","year":"2014","unstructured":"Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7392\u2013402.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"2716_CR26","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","volume":"145","author":"P Angulo","year":"2013","unstructured":"Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(4):782-789e784.","journal-title":"Gastroenterology"},{"issue":"1","key":"2716_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/liv.14649","volume":"41","author":"Z Xin","year":"2021","unstructured":"Xin Z, Liu S, Niu J, et al. The association of low-grade albuminuria with incident non-alcoholic fatty liver disease and non-invasive markers of liver fibrosis by glycaemia status. Liver Int. 2021;41(1):101\u20139.","journal-title":"Liver Int"},{"issue":"5","key":"2716_CR28","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/ajg.2016.453","volume":"112","author":"S McPherson","year":"2017","unstructured":"McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740\u201351.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"2716_CR29","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/STROKEAHA.124.046811","volume":"55","author":"M Han","year":"2024","unstructured":"Han M, Huang K, Shen C, et al. Discordant high remnant cholesterol with LDL-C increases the risk of stroke: a Chinese prospective cohort study. Stroke. 2024;55(8):2066\u201374.","journal-title":"Stroke"},{"issue":"4","key":"2716_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.ajkd.2023.08.016","volume":"83","author":"Y Li","year":"2024","unstructured":"Li Y, Wu S, Gao J, et al. Association of stroke with metabolic dysfunction-associated fatty liver disease with and without CKD. Am J Kidney Dis. 2024;83(4):477\u201388.","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"2716_CR31","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560\u201372.","journal-title":"JAMA"},{"issue":"41","key":"2716_CR32","first-page":"113","volume":"42","author":"Diabetes A American A. 2.","year":"2019","unstructured":"Diabetes A American A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(41):113.","journal-title":"Diabetes Care"},{"key":"2716_CR33","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","volume":"14","author":"JJ Li","year":"2023","unstructured":"Li JJ, Zhao SP, Zhao D, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2716_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1053\/j.gastro.2024.03.017","volume":"167","author":"LA van Kleef","year":"2024","unstructured":"van Kleef LA, Francque SM, Prieto-Ortiz JE, et al. Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction. Gastroenterology. 2024;167(2):357\u2013367359.","journal-title":"Gastroenterology"},{"issue":"3","key":"2716_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/00325481.2018.1444901","volume":"130","author":"H Wang","year":"2018","unstructured":"Wang H, Chen Y, Sun G, et al. Validity of cardiometabolic index, lipid accumulation product, and body adiposity index in predicting the risk of hypertension in Chinese population. Postgrad Med. 2018;130(3):325\u201333.","journal-title":"Postgrad Med"},{"issue":"8","key":"2716_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1080\/00325481.2017.1375714","volume":"129","author":"H Wang","year":"2017","unstructured":"Wang H, Chen Y, Guo X, et al. Usefulness of cardiometabolic index for the estimation of ischemic stroke risk among general population in rural China. Postgrad Med. 2017;129(8):834\u201341.","journal-title":"Postgrad Med"},{"issue":"1","key":"2716_CR37","doi-asserted-by":"publisher","first-page":"13194","DOI":"10.1038\/s41598-024-64034-3","volume":"14","author":"L Yan","year":"2024","unstructured":"Yan L, Hu X, Wu S, et al. Association between the cardiometabolic index and NAFLD and fibrosis. Sci Rep. 2024;14(1):13194.","journal-title":"Sci Rep"},{"issue":"3","key":"2716_CR38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s42000-024-00572-9","volume":"23","author":"L Cheng","year":"2024","unstructured":"Cheng L, Wu Q, Wang S. Association between cardiometabolic index and hepatic steatosis and liver fibrosis: a population-based study. Hormones (Athens). 2024;23(3):477\u201386.","journal-title":"Hormones (Athens)"},{"issue":"4","key":"2716_CR39","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41366-021-00743-3","volume":"45","author":"K Meredith-Jones","year":"2021","unstructured":"Meredith-Jones K, Taylor R, Brown R, et al. Age- and sex-specific visceral fat reference cutoffs and their association with cardio-metabolic risk. Int J Obes (Lond). 2021;45(4):808\u201317.","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"2716_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-023-01886-5","volume":"22","author":"B Yin","year":"2023","unstructured":"Yin B, Wu Z, Xia Y, et al. Non-linear association of atherogenic index of plasma with insulin resistance and type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol. 2023;22(1):157.","journal-title":"Cardiovasc Diabetol"},{"issue":"36","key":"2716_CR41","doi-asserted-by":"publisher","first-page":"5364","DOI":"10.3748\/wjg.v28.i36.5364","volume":"28","author":"SJ Duan","year":"2022","unstructured":"Duan SJ, Ren ZY, Zheng T, et al. Atherogenic index of plasma combined with waist circumference and body mass index to predict metabolic-associated fatty liver disease. World J Gastroenterol. 2022;28(36):5364\u201379.","journal-title":"World J Gastroenterol"},{"key":"2716_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.969783","volume":"13","author":"K Li","year":"2022","unstructured":"Li K, Li J, Cheng X, et al. Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants. Front Endocrinol (Lausanne). 2022;13: 969783.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2716_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-022-01511-x","volume":"21","author":"LC Tao","year":"2022","unstructured":"Tao LC, Xu JN, Wang TT, et al. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2716_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12933-021-01443-y","volume":"21","author":"Y Jiao","year":"2022","unstructured":"Jiao Y, Su Y, Shen J, et al. Evaluation of the long-term prognostic ability of triglyceride-glucose index for elderly acute coronary syndrome patients: a cohort study. Cardiovasc Diabetol. 2022;21(1):3.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2716_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12933-021-01332-4","volume":"20","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Liu K, Chen M, et al. Triglyceride-glucose index is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents. Cardiovasc Diabetol. 2021;20(1):137.","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"2716_CR46","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.2337\/dc18-1920","volume":"42","author":"K Park","year":"2019","unstructured":"Park K, Ahn CW, Lee SB, et al. Elevated TyG index predicts progression of coronary artery calcification. Diabetes Care. 2019;42(8):1569\u201373.","journal-title":"Diabetes Care"},{"key":"2716_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108786","volume":"177","author":"W Guo","year":"2021","unstructured":"Guo W, Zhao L, Mo F, et al. The prognostic value of the triglyceride glucose index in patients with chronic heart failure and type 2 diabetes: a retrospective cohort study. Diabetes Res Clin Pract. 2021;177: 108786.","journal-title":"Diabetes Res Clin Pract"},{"key":"2716_CR48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.clnesp.2021.04.025","volume":"44","author":"H Tutunchi","year":"2021","unstructured":"Tutunchi H, Naeini F, Mobasseri M, et al. Triglyceride glucose (TyG) index and the progression of liver fibrosis: a cross-sectional study. Clin Nutr ESPEN. 2021;44:483\u20137.","journal-title":"Clin Nutr ESPEN"},{"issue":"1","key":"2716_CR49","doi-asserted-by":"publisher","first-page":"2409342","DOI":"10.1080\/07853890.2024.2409342","volume":"56","author":"F Zhang","year":"2024","unstructured":"Zhang F, Han Y, Wu Y, et al. Association between triglyceride glucose-body mass index and the staging of non-alcoholic steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Ann Med. 2024;56(1):2409342.","journal-title":"Ann Med"},{"issue":"79\u201385","key":"2716_CR50","volume":"242","author":"K Song","year":"2022","unstructured":"Song K, Park G, Lee HS, et al. Comparison of the triglyceride glucose index and modified triglyceride glucose indices to predict nonalcoholic fatty liver disease in youths. J Pediatr. 2022;242(79\u201385): e71.","journal-title":"J Pediatr"},{"key":"2716_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111315","volume":"137","author":"B Ahmed","year":"2021","unstructured":"Ahmed B, Sultana R, Greene MW. Adipose tissue and insulin resistance in obese. Biomed Pharmacother. 2021;137: 111315.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2716_CR52","doi-asserted-by":"publisher","first-page":"327","DOI":"10.4093\/dmj.2023.0350","volume":"48","author":"I Jung","year":"2024","unstructured":"Jung I, Koo DJ, Lee WY. Insulin resistance, non-alcoholic fatty liver disease and type 2 diabetes mellitus: clinical and experimental perspective. Diabetes Metab J. 2024;48(3):327\u201339.","journal-title":"Diabetes Metab J"},{"issue":"2","key":"2716_CR53","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/19768354.2014.906502","volume":"18","author":"YJ Lee","year":"2014","unstructured":"Lee YJ, Yu JH, Kim W-H, et al. New mechanisms contributing to hepatic steatosis: glucose, insulin, and lipid signaling. Animal Cells Syst. 2014;18(2):77\u201382.","journal-title":"Animal Cells Syst"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02716-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02716-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T09:59:48Z","timestamp":1743847188000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02716-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2716"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02716-6","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"7 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the Declaration of Helsinki and was approved by the Ethics Review Committee of the Second Hospital of Dalian Medical University (2022064). All participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}